--- title: "Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 Breakouts" type: "News" locale: "en" url: "https://longbridge.com/en/news/292180952.md" description: "The US clinical-stage biotech and CXO sector is undergoing significant restructuring. Backed by major clinical data readouts and massive financing rounds announced recently, we look into seven key players shaping the industry's trajectory this year." datetime: "2026-07-09T10:02:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292180952.md) - [en](https://longbridge.com/en/news/292180952.md) - [zh-HK](https://longbridge.com/zh-HK/news/292180952.md) --- # Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 Breakouts The US clinical-stage biotech and CXO sector is undergoing its most significant overhaul in recent memory. Following a flurry of critical clinical data presentations at major medical conferences and a wave of massive financing rounds earlier this year, I'm told that the industry is gearing up for an incredibly active second half of 2026. Institutional attention is rapidly shifting toward early-to-late clinical assets, particularly in immuno-oncology, metabolic diseases, and central nervous system treatments. ### BIOVENTUS INC (BVS.US) Following the successful spin-off of its advanced rehabilitation business in early 2025, BIOVENTUS INC (BVS.US) is now laser-focused on its pain treatments and surgical solutions. According to people familiar with the matter, internal leadership is highly optimistic following a strong first quarter in 2026, where the company reported USD 132.1M in revenue—a 6.6% year-over-year increase. With adjusted EBITDA jumping 24% to USD 23.9M, the company has confidently raised its full-year earnings and cash flow guidance. We will likely hear more details at the upcoming Goldman Sachs Healthcare Conference. ### ALTIMMUNE INC (ALT.US) In the highly competitive metabolic disease space, ALTIMMUNE INC (ALT.US) is making serious waves with its dual-agonist Pemvidutide. I'm told that the 48-week IMPACT Phase 2b data presented at EASL in May 2026—showing a 23.7% reduction in triglycerides and 7.5% weight loss at the 1.8 mg dose—has emboldened the company. Backed by a recently completed, massively oversubscribed public offering that raked in USD 225M in April, the company is fully funded for its global Phase 3 PERFORMA trial expected to launch later this year. ### BLACK DIAMOND THERAPEUTICS INC (BDTX.US) This clinical-stage oncology firm is developing MasterKey therapies targeting oncogene families, and its recent data readouts are turning heads. BLACK DIAMOND THERAPEUTICS INC (BDTX.US) recently posted impressive numbers for its fourth-generation inhibitor Silevertinib in non-small cell lung cancer (NSCLC), demonstrating a 60% objective response rate (ORR) and a striking 86% ORR in the central nervous system. I understand that the company is currently exploring an accelerated FDA approval pathway, supported by a healthy cash reserve of USD 118.3M that should fund operations well into the second half of 2028. ### COLLEGIUM PHARMACEUTICAL INC (COLL.US) COLLEGIUM PHARMACEUTICAL INC (COLL.US) has been quietly building a formidable operational portfolio. The company generated USD 193.5M in net revenue in Q1 2026, up 9% year-over-year, driven largely by a 36% surge in Jornay PM quarterly net revenue. I'm told that the mid-May 2026 acquisition of the ADHD drug AZSTARYS is viewed internally as a massive win, extending their patent protection runway out to 2037 and prompting management to swiftly raise their 2026 financial guidance. ### Also - **PYXIS ONCOLOGY INC (PYXS.US)**: The company announced a USD 114M private placement on June 30, 2026. This massive capital injection is earmarked to push its core asset, MICVO, through critical clinical milestones, with updated Phase 2 monotherapy data in head and neck squamous cell carcinoma expected by Q4 2026. - **AKTIS ONCOLOGY INC (AKTS.US)**: This targeted radiopharmaceuticals developer reported its first-in-human clinical imaging data for AKY-2519 in May 2026, demonstrating strong tumor uptake and limited normal tissue exposure. A Phase 1b trial in metastatic castration-resistant prostate cancer is also officially underway. - **BURNING ROCK BIOTECH LTD (BNR.US)**: Despite a tough Q1 2026 that saw total revenue drop 18.9% to RMB 107.9M, the founder and CEO of BURNING ROCK BIOTECH LTD (BNR.US) has been aggressively accumulating shares. According to filings from early July, he has invested nearly USD 2M in ADS shares from the open market, signaling strong insider confidence to the street. _This article does not constitute investment advice._ ### Related Stocks - [BVS.US](https://longbridge.com/en/quote/BVS.US.md) - [ALT.US](https://longbridge.com/en/quote/ALT.US.md) - [BDTX.US](https://longbridge.com/en/quote/BDTX.US.md) - [COLL.US](https://longbridge.com/en/quote/COLL.US.md) - [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md) - [AKTS.US](https://longbridge.com/en/quote/AKTS.US.md) - [BNR.US](https://longbridge.com/en/quote/BNR.US.md) ## Related News & Research - [ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinence](https://longbridge.com/en/news/294057380.md) - [Altimmune's drug meets main goal of mid-stage study for alcohol use disorder](https://longbridge.com/en/news/294056614.md) - [Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD](https://longbridge.com/en/news/294056102.md) - [Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial](https://longbridge.com/en/news/294079208.md) - [Brookfield Infrastructure to fold BIPC, BIP into newly formed Brookfield Infrastructure Partners Inc. under arrangement deal](https://longbridge.com/en/news/294108647.md)